NewsBenzingaLe azioni di Novocure scendono dopo che la FDA respinge il suo dispositivo per il trattamento del cancro Le azioni di Novocure scendono dopo che la FDA respinge il suo dispositivo per il trattamento del cancro Benzinga 2026.11.09 16:26 (GMT+0) Open on Benzinga Other news Nvidia’s $105 Billion OpenAI Bet Has a 20-Year Catch Freedom Broker Upgrades Espey Manufacturing to Buy, Maintains Price Target to $70 QUICK SPARK: Chip Stocks Eye Worst Two-Month Drop Since 2008 Carlyle, Clearlake Bet Big On Sports — And PE Deals Are Surging Target's $301 Million Tariff Windfall 'Flattered' Earnings, Analyst Says Freedom Broker Maintains Buy on SKYX Platforms, Lowers Price Target to $2